Treatment of Cerebral Arteriovenous Malformation in Unruptured Brain AVM
Managing a cerebral arteriovenous malformation that has not yet bled presents a distinct clinical challenge. The optimal approach for unruptured brain AVMs remains an area of active debate, given the limited high-quality evidence available to guide decision-making.
Clinical Scenario
This protocol addresses patients with an unruptured brain arteriovenous malformation (bAVM). The evidence base is narrow: only one randomised controlled trial has been conducted to inform management in this population. The lifetime risks of intracranial haemorrhage, the predictors of those risks, and the complications associated with various treatment approaches remain incompletely characterised.
Treatment Approach
The management of unruptured brain AVMs involves a conservative strategy. Evidence has supported a non-interventional direction in selected patients — but the full scope of the protocol, including when and how to apply it, is detailed in the structured regimen.
Complete protocol — including sequencing, decision points, and patient-selection criteria — available via the link below.
References
DOI: 10.1161/STR.0000000000000134
- The optimal approach to management of unruptured bAVMs remains a subject of debate because of insufficient high-quality, consistent evidence about the lifetime risks of ICH and its predictors and the complications associated with treatment.
- Only 1 randomized controlled trial exists to inform the management of unruptured bAVMs: ARUBA.
- The National Institute of Neurological Disorders and Stroke stated that "under the experimental conditions in this trial, the interim analysis of data collected to date shows that medical management is superior to intervention in patients with unruptured brain arteriovenous malformations."
- Although these 2 studies support a more conservative approach to unruptured bAVMs, they suffer from 2 major limitations that weaken the conclusions.
View source ↗